Santa Clara-based Affymetrix (NASDAQ:AFFX) said the purchase price was about $315 million in cash, funded through a new senior secured credit facility, an offering of convertible notes and other cash resources. The price is lower than a previously announced $330 million.
Showing posts with label Affymetrix. Show all posts
Showing posts with label Affymetrix. Show all posts
Tuesday, June 26, 2012
Wednesday, December 28, 2011
Affymetrix acquisition of eBioscience hits delay
Affymetrix Inc.'s previously announced acquisition of San Diego-based eBioscience Inc. has been delayed, according to StreetInsider.com on Wednesday.
The deal was previously expected to close in the fourth quarter of 2011, but is now expected to wrap up in January 2012. The delay is due to additional work required to complete the merger's debt financing, StreetInsider reports.
The deal was previously expected to close in the fourth quarter of 2011, but is now expected to wrap up in January 2012. The delay is due to additional work required to complete the merger's debt financing, StreetInsider reports.
Wednesday, November 30, 2011
Affymetrix to buy eBioscience for $330M
Affymetrix Inc. said Wednesday it signed an agreement to acquire eBioscience Inc.
Santa Clara-based Affymetrix (NASDAQ:AFFX) said the purchase price is $330 million in cash, subject to certain customary adjustments. Affymetrix makes products and services related to genetic analysis for the life science research and clinical health care markets.
San Diego-based eBioscience is a private company specializing in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics. EBioscience is expected to have 2011 sales of more than $70 million.
Santa Clara-based Affymetrix (NASDAQ:AFFX) said the purchase price is $330 million in cash, subject to certain customary adjustments. Affymetrix makes products and services related to genetic analysis for the life science research and clinical health care markets.
San Diego-based eBioscience is a private company specializing in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics. EBioscience is expected to have 2011 sales of more than $70 million.
Thursday, July 21, 2011
UCSF, Kaiser team with Affymetrix to unlock genetic data in 100K-person study
The $24.8 million project, funded by the National Institutes of Health’s federal stimulus program outlay, is significant in several ways.
Thursday, July 7, 2011
Affymetrix stock dives on lower Q2 guidance
Affymetrix Inc. said Wednesday its preliminary second-quarter revenue declined to $64 million to $65 million because of lower academic and consumables sales.
The news sent the Santa Clara-based company's (NASDAQ:AFFX) stock down after hours almost 18 percent.
The news sent the Santa Clara-based company's (NASDAQ:AFFX) stock down after hours almost 18 percent.
Wednesday, June 1, 2011
Affymetrix CEO steps down, replaced by former Dionex CEO
Affymetrix Inc. on Wednesday named Frank Witney president and CEO.
Santa Clara-based Affymetrix (NASDAQ:AFFX) said Witney has 30 years of experience in the life science research products and diagnostic and analytical instrument industry and worked in senior leadership positions at Dionex, Panomics, Affymetrix and Bio-Rad.
Witney, who will also join the company’s board of directors, succeeds Kevin M. King who has resigned as Affymetrix’s president and chief executive officer to pursue other interests.
Santa Clara-based Affymetrix (NASDAQ:AFFX) said Witney has 30 years of experience in the life science research products and diagnostic and analytical instrument industry and worked in senior leadership positions at Dionex, Panomics, Affymetrix and Bio-Rad.
Witney, who will also join the company’s board of directors, succeeds Kevin M. King who has resigned as Affymetrix’s president and chief executive officer to pursue other interests.
Subscribe to:
Posts (Atom)